Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6304-6309

  Katiyar, Santosh K ^a   Alastruey Izquierdo, Ana ^b,c   Healey, Kelley R ^a   Johnson, Michael E ^a,d   Perlin, David S ^b   Edlind, Thomas D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; FUNGAL PROTEIN; PROTEIN FKS1; PROTEIN FKS2; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOLOGICAL ACTIVITY; CANDIDA GLABRATA; CODON; FUNGAL STRAIN; FUNGUS GROWTH; IN VITRO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; WILD TYPE;

ANTIFUNGAL AGENTS; CALCINEURIN; CANDIDA GLABRATA; CULTURE MEDIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GENES, FUNGAL; GLUCOSYLTRANSFERASES; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; PLASMIDS; POLYMERASE CHAIN REACTION; RNA; TACROLIMUS;

EID: 84869203438     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00813-12     Document Type: Article

References (45)

1. Arevalo-Rodriguez M, Wu X, Hanes SD, Heitman J. 2004. Prolyl isomerases in yeast. Front. Biosci. 9:2420-2446.
2. Balashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
3. Castanheira M, et al. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659.
4. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
5. Dannaoui E, et al. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg. Infect. Dis. 18:86-90.
6. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
7. Desnos-Ollivier M, et al. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
8. Douglas CM. 2001. Fungal β(1,3)-D-glucan synthesis. Med. Mycol. 39(Suppl 1):55-66.
9. Douglas CM, et al. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc. Natl. Acad. Sci. U. S. A. 91:12907-12911.
10. Douglas CM, et al. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
11. Dujon B, et al. 2004. Genome evolution in yeasts. Nature 430:35-44.
12. Edlind TD, et al. 2005. Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast. Curr. Genet. 48:117-125.
13. Garcia-Effron G, et al. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227.
14. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
15. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
16. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
17. Ha YS, Covert SF, Momany M. 2006. FsFKS1, the 1,3-β-glucan synthase from the caspofungin-resistant fungus Fusarium solani. Eukaryot. Cell 5:1036-1042.
18. Huang LS, Doherty HK, Herskowitz I. 2005. The Smk1p MAP kinase negatively regulates Gsc2p, a 1,3-beta-glucan synthase, during spore wall morphogenesis in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 102:12431-12436.
19. Inoue SB, et al. 1995. Characterization and gene cloning of 1,3-beta-D-glucan synthase from Saccharomyces cerevisiae. Eur. J. Biochem. 231:845-854.
20. Ishihara S, et al. 2007. Homologous subunits of 1,3-beta-glucan synthase are important for spore wall assembly in Saccharomyces cerevisiae. Eukaryot. Cell 6:143-156.
21. Johnson ME, Katiyar SK, Edlind TD. 2011. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob. Agents Chemother. 55:3774-3781.
22. Kahn JN, et al. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
23. Katiyar SK, Edlind TD. 2009. Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 53:1772-1778.
24. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
25. Kitada K, Yamaguchi E, Arisawa M. 1995. Cloning of the Candida glabrata TRP1 and HIS3 genes, and construction of their disruptant strains by sequential integrative transformation. Gene 165:203-206.
26. Laverdiere M, et al. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
27. Mazur P, et al. 1995. Differential expression and function of two homologous subunits of yeast 1,3-β-glucan synthase. Mol. Cell. Biol. 15:5671-5681.
28. Messer SA, Jones RN, Moet GJ, Kirby JT, Castanheira M. 2010. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the Global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 48:2984-2987.
29. Mio T, et al. 1997. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in β-1,3-glucan synthesis. J. Bacteriol. 179:4096-4105.
30. Niimi K, et al. 2010. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J. Antimicrob. Chemother. 65:842-852.
31. Ohyama T, Miyakoshi S, Isono F. 2004. FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-β-glucan synthase inhibitor arborcandin C. Antimicrob. Agents Chemother. 48:319-322.
32. Ostrosky-Zeichner L, et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
33. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
34. Park S, et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
35. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
36. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45. doi:10.1093/nar/29.9.e45.
37. Pfaller MA, et al. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
38. Pfaller M, et al. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J. Clin. Microbiol. 49:624-629.
39. Pfaller MA, et al. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50:1199-1203.
40. Pfeiffer CD, et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
41. Roetzer A, Gabaldón T, Schüller C. 2011. From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: important adaptations for an opportunistic pathogen. FEMS Microbiol. Lett. 314:1-9.
42. Singh N, Heitman J. 2004. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 77:795-800.
43. Thompson JR, et al. 1999. A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. 181:444-453.
44. Vermitsky J-P, Edlind TD. 2004. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob. Agents Chemother. 48:3773-3781.
45. Zimbeck AJ, et al. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54:5042-5047.